Hydroxyethyl starch 130/0.4 and sodium chloride injection as adjunctive therapy in patients with cerebral hypoperfusion

Junliang Han, Fang Yang, Wenrui Jiang, Guangyun Zhang, Zhirong Liu, Xuedong Liu, Feng Xia, Ya Bai, Junhong He, Manxiang Chao, Gang Zhao, Junliang Han, Fang Yang, Wenrui Jiang, Guangyun Zhang, Zhirong Liu, Xuedong Liu, Feng Xia, Ya Bai, Junhong He, Manxiang Chao, Gang Zhao

Abstract

Background: Both severe stenosis and completed occlusion in internal carotid artery or its distal branches have been considered the main reasons of cerebral hypoperfusion, which contributes to the washout disturbances of embolism in low perfusion territories distal to stenosis. An aggravated hypoperfusion state in certain brain region may induce ischemic stroke and further cognitive decline. However, the effective medication for cerebral hypoperfusion is largely unsettled.

Methods/design: By using computed tomography perfusion (CTP) imaging, the trial will evaluate the effectiveness, safety and tolerability of hydroxyethyl starch (HES) 130/0.4 for patients with extra-/intra-cranial artery stenosis and cerebral hypoperfusion. From 5 neurological inpatient wards, 300 patients will be randomly recruited for administered routine medications plus intravascular volume therapies using the equal volume of HES 130/0.4 or 0.9% sodium chloride solution. Cerebral hypoperfusion state after 7-day intervention is the primary outcome measure. The secondary outcome measures includes, impaired renal function, abnormal heart function, hematological changes, neurological dysfunctions and cerebrovascular events in peri-intervention period and/or 3-month follow-up. The sample size will allow the detection of a two-sided 5% significance level between groups in the endpoint with a power of 80%.

Discussion: The trial would provide important efficacy and safety data on the intravascular administration of HES 130/0.4 in patients with unilateral cerebral hypoperfusion. The effects on kidney function, heart function, coagulation, neurological function and cerebralvascular events will be assessed.

Trial registration: ClinicalTrials.gov (Identifier: NCT01192581).

Figures

Figure 1
Figure 1
Flowchart outlining the trial protocol.

References

    1. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35–41. doi: 10.1161/01.STR.24.1.35.
    1. Gao S, Wang YJ, Xu AD, Li YS, Wang DZ. Chinese ischemic stroke subclassification. Front Neurol. 2011;2:6.
    1. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325(7):445–453.
    1. European Carotid Surgery Trialists’ Collaborative Group European MRC. Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) or with mild (0-29%) carotid stenosis. Lancet. 1991;337(8752):1235–1243. doi: 10.1016/0140-6736(91)92916-P.
    1. Caplan LR, Wong KS, Gao S, Hennerici MG. Is hypoperfusion an important cause of strokes? If so, how? Cerebrovasc Dis. 2006;21(3):145–153. doi: 10.1159/000090791.
    1. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN. et al.Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42(1):227–276. doi: 10.1161/STR.0b013e3181f7d043.
    1. Wholey MH, Wholey M, Mathias K, Roubin GS, Diethrich EB, Henry M, Bailey S, Bergeron P, Dorros G, Eles G. et al.Global experience in cervical carotid artery stent placement. Catheter Cardiovasc Interv. 2000;50(2):160–167. doi: 10.1002/(SICI)1522-726X(200006)50:2<160::AID-CCD2>;2-E.
    1. CAVATAS investigators. Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial. Lancet. 2001;357(9270):1729–1737.
    1. Rothwell PM, Eliasziw M, Gutnikov SA, Fox AJ, Taylor DW, Mayberg MR, Warlow CP, Barnett HJ. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet. 2003;361(9352):107–116. doi: 10.1016/S0140-6736(03)12228-3.
    1. Aoyagi J, Ikeda K, Kiyozuka T, Hirayama T, Ishikawa Y, Sato R, Yoshii Y, Kawabe K, Iwasaki Y. Alleviation of brain hypoperfusion after preventative treatment with lomerizine in an elderly migraineur with aura. Int J Mol Imaging. 2011;2011:782758.
    1. Strand T. Evaluation of long-term outcome and safety after hemodilution therapy in acute ischemic stroke. Stroke. 1992;23(5):657–662. doi: 10.1161/01.STR.23.5.657.
    1. Strand T, Asplund K, Eriksson S, Hagg E, Lithner F, Wester PO. A randomized controlled trial of hemodilution therapy in acute ischemic stroke. Stroke. 1984;15(6):980–989. doi: 10.1161/01.STR.15.6.980.
    1. Aichner FT, Fazekas F, Brainin M, Polz W, Mamoli B, Zeiler K. Hypervolemic hemodilution in acute ischemic stroke: the Multicenter Austrian Hemodilution Stroke Trial (MAHST) Stroke. 1998;29(4):743–749. doi: 10.1161/01.STR.29.4.743.
    1. Asplund K. Haemodilution for acute ischaemic stroke. Cochrane Database Syst Rev. 2002;4:CD000103.
    1. Treib J, Grauer MT, Woessner R, Morgenthaler M. Treatment of stroke on an intensive stroke unit: a novel concept. Intensive Care Med. 2000;26(11):1598–1611. doi: 10.1007/s001340000667.
    1. Haass A, Kroemer H, Jager H, Muller K, Decker I, Schimrigk K, Wagner EM. [Dextran 40 or HES 200/0.5? Hemorheology of the long-term treatment of ischemic cerebral attacks] Dtsch Med Wochenschr. 1986;111(44):1681–1686. doi: 10.1055/s-2008-1068692.
    1. Neff TA, Fischler L, Mark M, Stocker R, Reinhart WH. The influence of two different hydroxyethyl starch solutions (6% HES 130/0.4 and 200/0.5) on blood viscosity. Anesth Analg. 2005;100(6):1773–1780. doi: 10.1213/01.ANE.0000149326.45137.9A.
    1. Standl T, Burmeister MA, Schroeder F, Currlin E, Schulte am Esch J, Freitag M. Hydroxyethyl starch (HES) 130/0.4 provides larger and faster increases in tissue oxygen tension in comparison with prehemodilution values than HES 70/0.5 or HES 200/0.5 in volunteers undergoing acute normovolemic hemodilution. Anesth Analg. 2003;96(4):936–943. table of contents.
    1. Wang P, Li Y, Li J. Protective roles of hydroxyethyl starch 130/0.4 in intestinal inflammatory response and oxidative stress after hemorrhagic shock and resuscitation in rats. Inflammation. 2009;32(2):71–82. doi: 10.1007/s10753-009-9105-7.
    1. Allmark P, Mason S. Improving the quality of consent to randomised controlled trials by using continuous consent and clinician training in the consent process. J Med Ethics. 2006;32(8):439–443. doi: 10.1136/jme.2005.013722.
    1. Nederkoorn PJ, van der Graaf Y, Hunink MG. Duplex ultrasound and magnetic resonance angiography compared with digital subtraction angiography in carotid artery stenosis: a systematic review. Stroke. 2003;34(5):1324–1332. doi: 10.1161/01.STR.0000068367.08991.A2.
    1. Wintermark M, Sincic R, Sridhar D, Chien JD. Cerebral perfusion CT: technique and clinical applications. J Neuroradiol. 2008;35(5):253–260. doi: 10.1016/j.neurad.2008.03.005.
    1. Woessner R, Grauer MT, Dieterich HJ, Bepperling F, Baus D, Kahles T, Georgi S, Bianchi O, Morgenthaler M, Treib J. Influence of a long-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 or crystalloid solution on hemodynamics, rheology and hemostasis in patients with acute ischemic stroke. Results of a randomized, placebo-controlled, double-blind study. Pathophysiol Haemost Thromb. 2003;33(3):121–126. doi: 10.1159/000077819.
    1. Rudolf J. Hydroxyethyl starch for hypervolemic hemodilution in patients with acute ischemic stroke: a randomized, placebo-controlled phase II safety study. Cerebrovasc Dis. 2002;14(1):33–41. doi: 10.1159/000063721.
    1. Neff TA, Doelberg M, Jungheinrich C, Sauerland A, Spahn DR, Stocker R. Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesth Analg. 2003;96(5):1453–1459. table of contents.
    1. Lee JS, Ahn SW, Song JW, Shim JK, Yoo KJ, Kwak YL. Effect of hydroxyethyl starch 130/0.4 on blood loss and coagulation in patients with recent exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass graft surgery. Circ J. 2011;75(10):2397–2402. doi: 10.1253/circj.CJ-11-0404.
    1. Hartog CS, Kohl M, Reinhart K. A systematic review of third-generation hydroxyethyl starch (HES 130/0.4) in resuscitation: safety not adequately addressed. Anesth Analg. 2011;112(3):635–645. doi: 10.1213/ANE.0b013e31820ad607.
    1. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in acute ischemic stroke. i. results in the total patient population. Scandinavian Stroke Study Group. Stroke. 1987;18(4):691–699.
    1. Ghogawala Z, Westerveld M, Amin-Hanjani S. Cognitive outcomes after carotid revascularization: the role of cerebral emboli and hypoperfusion. Neurosurgery. 2008;62(2):385–395. doi: 10.1227/01.neu.0000316005.88517.60. discussion 393–385.
    1. Payabvash S, Souza LC, Wang Y, Schaefer PW, Furie KL, Halpern EF, Gonzalez RG, Lev MH. Regional ischemic vulnerability of the brain to hypoperfusion: the need for location specific computed tomography perfusion thresholds in acute stroke patients. Stroke. 2011;42(5):1255–1260. doi: 10.1161/STROKEAHA.110.600940.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj